Transcept Pharmaceuticals TSPT today announced the dismissal of the derivative lawsuit by the Court of Chancery of the State of Delaware. The derivative lawsuit was filed on October 24, 2013, by a shareholder, Retrophin Inc., against the Transcept Board of Directors, purporting to assert claims on behalf of Transcept, alleging that our Board of Directors approved and paid excessive compensation to our directors.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in